Title of Invention: BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS Abstract: The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic. Detailed Description: FIELD OF THE INVENTION This invention relates to novel biaryl monobactam compounds, processes for their preparation and their use as therapeutic agents. More particularly, the invention relates to biaryl monobactam compounds and their use as antibiotic agents for the treatment of bacterial infections. BACKGROUND OF THE INVENTION The introduction of antibiotics for treatment of bacterial infections is one of the great medical achievements of the 20th century. Over the past few decades, however, bacteria resistant to multiple antibiotics have begun to emerge throughout the world, threatening the effectiveness of antibiotic therapy. In the United States alone, at least 23,000 people each year die as a direct result of infections caused by antibiotic-resistant bacteria, and numerous others die from pre-existing conditions exacerbated by similar infections. Antibiotic Resistance Threats in the United States, 2013, Centers for Disease Control, Atlanta, Ga. New antibiotics are needed to combat the current and future threat of multidrug resistant bacteria. β-lactams are the most widely used antibiotics for treatment of serious bacterial infections. These include carbapenems, cephalosporins, penicillins, and monobactams. As has been observed for other antibiotic classes, resistance to β-lactams has emerged. For most Gram-negative bacteria, this resistance is primarily driven by the expression of β-lactamases, enzymes that hydrolyze β-lactam compounds. There are 4 different classes of β-lactamases (A, B, C, and D) capable of hydrolyzing overlapping but distinct subsets of β-lactams (Drawz and Bonomo, Clin. Micro. Rev., 2010, 23:160-201). While the class B β-lactamases, also known as metallo β-lactamases (MBLs), are not the most prevalent β-lactamases found in the clinic, the frequency and distribution of their expression is on the rise and represent a significant medical threat because (i) MBLs have to ability to hydrolze all β-lactams except monobactams, and (ii) unlike the class A and C β-lactamases, there are no inhibitors available for the MBLs. Aztreonam, a monobactam, was first approved in the U.S in 1986 for the treatment of aerobic Gram-negative bacterial infections and remains the only monobactam in use in the U.S. today. However, aztreonam has poor activity against Pseudomonas and Acinetobacter strains. Because monobactams are inherently resistant to hydrolysis by MBLs, several companies have begun developing novel monobactam compounds for the treatment of infections caused by Gram-negative bacteria. Monobactam compounds comprising a siderophore moiety are disclosed in WO 2007/065288, WO2012/073138, J. Medicinal Chemistry 56: 5541-5552 (2013), and Bioorganic and Medicinal Chemistry Letters 22:5989 (2012). U.S. Patent Application Publication No. US 2014/0275007 discloses oxamazin monobactams and their use as antibacterial agents, and U.S. Patent Application Publication No. US 2015/0266867 also discloses novel monobactam compounds for the use as antibacterial agents. International Patent Application Publication No. WO (207)955-4663 discloses novel amidine substituted monobactam derivatives and their use as antimicrobial reagents. The need for new antibiotics to overcome multidrug resistance continues. Compounds disclosed in this invention are designed to fill this medical need, through administration either on their own or in combination with a suitable β-lactamase inhibitor. SUMMARY OF THE INVENTION The invention relates to the design and synthesis of a series of bi-aryl monobactam analogs, a novel class of highly potent antibiotics effective against a broad range of Gram-negative bacteria. These compounds and their pharmaceutically acceptable salts may be useful as therapeutic agents for clinical treatment of various infections caused by Gram-negative bacteria, including strains that are multidrug resistant. The compounds can be used alone or in combination with a suitable β-lactamase inhibitor. More particularly, the present invention includes compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein: W is a bond or O; RX and RZ are independently hydrogen, —SC1-C3alkyl, C1-C3 alkyl, —(C1-C3alkylene)nOC1-C3alkyl, or —(C1-C3alkylene)nNC1-C3alkyl, wherein the —SC1-C3alkyl, the C1-C3 alkyl, the —(C1-C3alkylene)nOC1-C3alkyl and the —(C1-C3alkylene)nNC1-C3alkyl are optionally substituted with one to seven fluorines; or, alternatively, RX and RZ, together with the carbon to which they are attached, form a monocyclic C4-C7 cycloalkyl or a monocyclic C4-C7 heterocycloalkyl with 1, 2, or 3 heteroatom ring atoms independently selected from N, O and S, wherein said C4-C7 cycloalkyl and said C4-C7 heterocycloalkyl are optionally substituted with one to three substituents independently selected from —F, —OH and —OC1-C3alkyl; X is N or CR1; R1 is hydrogen, C1-C3 alkyl, or halogen; wherein said C1-C3 alkyl is optionally substituted with one to three Ra; each occurrence of Ra is independently hydrogen, halogen, C1-C3alkyl, —NRcRd or —ORe; Z is C1-C3 alkylene, optionally substituted with one to three Rb; each occurrence of Rb is independently —C1-C8 alkyl, —C3-C7 cycloalkyl, —C(O)ORe, —C(O)NRcRd, tetrazolyl, oxadiazolonyl, HetA, AryA, —S(O)mRe, —S(O)mNRcRd, or —P(O)(Re)p wherein said —C1-C8 alkyl and said —C3-C7 cycloalkyl are optionally substituted with one to three Ra; HetA is a 4- to 6-membered saturated or monounsaturated monocyclic ring with 1, 2, or 3 heteroatom ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4; AryA is a 5- to 6-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4; Y is a bond, O, NR2, S, or CH2; R2 is hydrogen, —C1-C3 alkyl, —C(O)Re—C(O)NRcRd, —S(O)mRe, or —S(O)mNRcRd wherein said —C1-C3 alkyl is optionally substituted with one to three Ra; A1 is AryA; A2 is —(CH2)nN(R3)2—, C3-C7 cycloalkyl, AryC or HetC, wherein said C3-C7 cycloalkyl is optionally substituted with one to four R4; AryC is a 5- to 6-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4; HetC is a 4- to 7-membered saturated or monounsaturated monocyclic ring with 1, 2, or 3 heteroatom ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4; each occurrence of R4 is independently: —C1-C8 alkyl, —C2-C8 alkenyl, —C2-C8 alkynyl, halogen, —ORe, —S(O)mRe, —S(O)mNRcRd, —C(O)Re, —OC(O)Re, —C(O)ORe, —CN, —C(O)NRcRd, —NRcRd, —(CH2)nNRcRd; —NRcC(O)Re, —NRcC(O)ORe, —NRcC(O)NRcRd, —NRcS(O)mRe, ═NH, —CF3, —OCF3, —OCHF2, —C3-C6 cycloalkyl, —O—C3-C6cycloalkyl, —C1-C10alkylene-C3-C6cycloalkyl, —O—C1-C10 alkylene-C3-C6cycloalkyl, HetB, —O-HetB, —C1-C10alkylene-HetB, —O—C1-C10 alkylene-HetB, AryA, —O-AryA, —C1-C10 alkylene-AryA, or —O—C1-C10alkylene-AryA, wherein each R4 is unsubstituted or substituted with one to four substituents selected from halogen, —C1-C6 alkyl and —(CH2)nNRcRd, or wherein R4 and M, together with the atoms to which they are attached, form a 4- to 7-membered cycloheteroalkyl optionally containing one to two additional heteroatoms independently selected from O, S and —NRg; HetB is a 3- to 6-membered saturated or monounsaturated monocyclic ring with 1, 2, or 3 heteroatom ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to three Ra; Q is a bond, CH2, O, S, —(CH2)nNR3—, or —NR3(CH2)n—, wherein each CH2 is unsubstituted or substituted with one to two substituents selected from halogen, —C1-C6 alkyl, ORe and —(CH2)nNRcRd; R3 is hydrogen or —C1-C3 alkyl, wherein said —C1-C3 alkyl is optionally substituted with one to three Ra; M is R5, —NHR5, —N(R5)2, —OR5, —(CH2)nR5, —C(O)R5, —C(NH)R5, or —S(O)mR5; R5 is H, C2-C10 alkyl, C3-C7 cycloalkyl, C1-C6 alkyl-C3-C7 cycloalkyl, HetB, AryB, or —NH(C1-C6 alkyl), wherein said C1-C6 alkyl, said C2-C10 alkyl and said C3-C7 cycloalkyl are optionally substituted with one to four R6; AryB is a 5- to 6-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, O and S, optionally substituted with one to four R4; each occurrence of R6 is independently selected from the group consisting of: halogen, —ORe, —S(O)mRe, —S(O)mNRcRd, —C(O)Re, —OC(O)Re—C(O)ORe, —CN, —C(O)NRcRd, —C(NH)NRcRd, —NcRd, —(CH2)nNRcRd, —N(Rc)(C(O)Re), —N(Rc)(C(O)ORe), —N(Rc)(C(O)NRcRd), —N(Rc)(S(O)mRe), and HetB; each occurrence of Rc and Rd is independently: hydrogen, —C1-C10 alkyl, —C2-C10 alkenyl, —C3-C6 cycloalkyl, —C1-C10 alkylene-C3-C6 cycloalkyl, HetA, —C1-C10alkylene-HetB, AryB, —C1-C10 alkylene-AryB, and —C1-C10 alkylene-HetB, or, alternatively, Rc and Rd together with the nitrogen atom to which they are attached, form a 4- to 7-membered cycloheteroalkyl optionally containing one to two additional heteroatoms independently selected from O, S and —NRg, and wherein each Rc and Rd is optionally substituted with one to three Rf; each occurrence of Re is independently: hydrogen, —C1-C10alkyl, —C2-C10 alkenyl, —OH, —OC1-C4 alkyl, —C3-C6 cycloalkyl, —C1-C10 alkylene-C3-C6 cycloalkyl, HetB, —C1-C10 alkylene-HetB, AryB, —C1-C10 alkylene-AryB, or —C1-C10 alkylene-HetB; wherein each Re is optionally substituted with one to three Rh; each occurrence of Rf is independently: halogen, —C1-C10 alkyl, —OH, —OC1-C4 alkyl, —S(O)mC1-C4 alkyl, —CN, —CF3, —OCHF2, —OCF3, or NH2, wherein said —C1-C10 alkyl is optionally substituted with one to three substituents independently selected from: —OH, halogen, cyano, and —S(O)2CH3; each occurrence of Rg is independently: hydrogen, —C(O)Re, and —C1-C10 alkyl, wherein said —C1-C10alkyl is optionally substituted with one to five fluorines; each occurrence of Rh is independently: halogen, —C1-C10alkyl, —OH, —OC1-C4 alkyl, —S(O)mC1-C4 alkyl, —CN, —CF3, —OCHF2, or —OCF3; wherein said —C1-C10 alkyl is optionally substituted with one to three substituents independently selected from: —OH, halogen, cyano, or —S(O)2CH3; each n is independently 0, 1, 2, 3 or 4; each m is independently 0, 1 or 2, and each p is independently 1 or 2. The present invention also includes compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein: W is a bond or O; RX and RZ are independently hydrogen, —SC1-C3alkyl, C1-C3 alkyl, —(C1-C3alkylene)nOC1-C3alkyl, or —(C1-C3alkylene)nNC1-C3alkyl, wherein the —SC1-C3alkyl, the C1-C3 alkyl, the —(C1-C3alkylene)nOC1-C3alkyl and the —(C1-C3alkylene)nNC1-C3alkyl are optionally substituted with one to seven fluorines; or, alternatively, RX and RZ, together with the carbon to which they are attached, form a monocyclic C4-C7 cycloalkyl or a monocyclic C4-C7 heterocycloalkyl with 1, 2, or 3 heteroatom ring atoms independently selected from N, O and S, wherein said C4-C7 cycloalkyl and said C4-C7 heterocycloalkyl are optionally substituted with one to three substituents independently selected from —F, —OH and —OC1-C3alkyl; X is N or CR1; R1 is hydrogen, C1-C3 alkyl, or halogen; wherein said C1-C3 alkyl is optionally substituted with one to three Ra; each occurrence of Ra is independently hydrogen, halogen, C1-C3alkyl, —NRcRd or —ORe; Z is C1-C3 alkylene, optionally substituted with one to three Rb; each occurrence of Rb is independently —C1-C8 alkyl, —C3-C7 cycloalkyl, —C(O)ORe, —C(O)NRcRd, tetrazolyl, oxadiazolonyl, HetA, AryA, —S(O)mRe, —S(O)mNRcRd, or —P(O)(Re)p wherein said —C1-C8 alkyl and said —C3-C7 cycloalkyl are optionally substituted with one to three Ra; HetA is a 4- to 6-membered saturated or monounsaturated monocyclic ring with 1, 2, or 3 heteroatom ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4; AryA is a 5- to 6-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4; Y is a bond, O, NR2, S, or CH2; R2 is hydrogen, —C1-C3 alkyl, —C(O)Re, —C(O)NRcRd, —S(O)mRe, or —S(O)mNRcRd wherein said —C1-C3 alkyl is optionally substituted with one to three Ra; A1 is AryA; A2 is C3-C7 cycloalkyl, AryC or HetC, wherein said C3-C7 cycloalkyl is optionally substituted with one to four R4; AryC is a 5- to 6-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4; HetC is a 4- to 7-membered saturated or monounsaturated monocyclic ring with 1, 2, or 3 heteroatom ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4; each occurrence of R4 is independently: —C1-C8 alkyl, —C2-C8 alkenyl, —C2-C8 alkynyl, halogen, —ORe, —S(O)mRe, —S(O)mNRcRd, —C(O)Re, —OC(O)Re—C(O)ORe, —CN, —C(O)NRcRd, —NRcRd, —NRcC(O)Re, —NRcC(O)ORe, —NRcC(O)NRcRd, —NRcS(O)mRe, ═NH, —CF3, —OCF3, —OCHF2, —C3-C6 cycloalkyl, —O—C3-C6cycloalkyl, —C1-C10alkylene-C3-C6cycloalkyl, —O—C1-C10 alkylene-C3-C6cycloalkyl, HetB, —O-HetB, —C1-C10alkylene-HetB, —O—C1-C10 alkylene-HetB, AryA, —O-AryA, —C1-C10 alkylene-AryA, or —O—C1-C10alkylene-AryA; HetB is a 3- to 6-membered saturated or monounsaturated monocyclic ring with 1, 2, or 3 heteroatom ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to three Ra; Q is a bond, CH2, O, S, —(CH2)nNR3—, or —NR3(CH2)n—; R3 is hydrogen or —C1-C3 alkyl, wherein said —C1-C3 alkyl is optionally substituted with one to three Ra; M is R5, —NR5, —OR5, —(CH2)nR5, —C(O)R5, —CH(NH)R5, or —S(O)mR5; R5 is C2-C10 alkyl, C3-C7 cycloalkyl, HetB, or AryB, wherein said C2-C10 alkyl and said C3-C7 cycloalkyl are optionally substituted with one to four R6; AryB is a 5- to 6-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, O and S, optionally substituted with one to four R4; each occurrence of R6 is independently selected from the group consisting of: halogen, —ORe, —S(O)mRe, —S(O)mNRcRd, —C(O)Re, —OC(O)Re—C(O)ORe, —CN, —C(O)NRcRd, —C(NH)NRcRd, —NRcRd, —N(Rc)(C(O)Re), —N(Rc)(C(O)ORe), —N(Rc)(C(O)NRcRd), and —N(Rc)(S(O)mRe); each occurrence of Rc and Rd is independently: hydrogen, —C1-C10 alkyl, —C2-C10 alkenyl, —C3-C6 cycloalkyl, —C1-C10 alkylene-C3-C6 cycloalkyl, HetA, —C1-C10alkylene-HetB, AryB, —C1-C10 alkylene-AryB, and —C1-C10 alkylene-HetB, or, alternatively, Rc and Rd together with the nitrogen atom to which they are attached, form a 4- to 7-membered cycloheteroalkyl optionally containing one to two additional heteroatoms independently selected from O, S and —NRg, and wherein each Rc and Rd is optionally substituted with one to three Rf; each occurrence of Re is independently: hydrogen, —C1-C10alkyl, —C2-C10 alkenyl, —OH, —OC1-C4 alkyl, —C3-C6 cycloalkyl, —C1-C10 alkylene-C3-C6 cycloalkyl, HetB, —C1-C10 alkylene-HetB, AryB, —C1-C10 alkylene-AryB, or —C1-C10 alkylene-HetB; wherein each Re is optionally substituted with one to three Rh; each occurrence of Rf is independently: halogen, —C1-C10 alkyl, —OH, —OC1-C4 alkyl, —S(O)mC1-C4 alkyl, —CN, —CF3, —OCHF2, or —OCF3; wherein said —C1-C10 alkyl is optionally substituted with one to three substituents independently selected from: —OH, halogen, cyano, and —S(O)2CH3; each occurrence of Rg is independently: hydrogen, —C(O)Re, and —C1-C10 alkyl, wherein said —C1-C10alkyl is optionally substituted with one to five fluorines; each occurrence of Rh is independently: halogen, —C1-C10 alkyl, —OH, —OC1-C4 alkyl, —S(O)mC1-C4 alkyl, —CN, —CF3, —OCHF2, or —OCF3; wherein said —C1-C10 alkyl is optionally substituted with one to three substituents independently selected from: —OH, halogen, cyano, or —S(O)2CH3; each n is independently 0, 1, 2, 3 or 4; each m is independently 0, 1 or 2, and each p is independently 1 or 2. The present invention also relates to a pharmaceutical composition for treating a bacterial infection in a subject, including infection with multidrug resistant Gram-negative bacterial strains, comprising a biaryl monobactam compound of the invention and a pharmaceutically acceptable carrier, diluent or excipient. The Compounds of Formula (I) (also referred to herein as the “biaryl monobactam compounds”) and pharmaceutically acceptable salts thereof can be useful, for example, for inhibiting the growth of Gram-negative bacterial strains, including but not limited to, Pseudomonas and Acinetobacter strains, and/or for treating or preventing the clinical manifestations thereof in a patient. The present invention is also directed to methods of treating Gram-negative bacterial infections in a subject in need of treatment thereof, comprising administering to the subject an effective amount of a biaryl monobactam compound of the invention. In specific embodiments of the invention, the method includes administration of a beta lactamase inhibitor compound. Embodiments, sub-embodiments and features of the present invention are either further described in or will be apparent from the ensuing description, examples and appended claims. DETAILED DESCRIPTION OF THE INVENTION The invention relates to novel biaryl monobactam analogs, a class of highly potent antibiotics effective against a broad range of Gram-negative bacteria. These compounds have utility as therapeutic agents for clinical treatment of various infections caused by Gram-negative bacteria, including strains that are multidrug resistant, and for the treatment or prevention of the clinical pathologies associated therewith. In each of the various embodiments of the compounds of the invention described herein, each variable including those of Formulas I, II-1, II-2, II-3, III-1, III-2, and III-3, and the various embodiments thereof, each variable is selected independently of the others unless otherwise indicated. The present invention encompasses all compounds of Formulas I, II-1, II-2, II-3, III-1, III-2, and III-3, and the various embodiments thereof, for example, any solvates, hydrates, stereoisomers, and tautomers of said compounds and of any pharmaceutically acceptable salts thereof. The Compounds of Formula (I) In one aspect, the present invention includes compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein for the Compounds of Formula (I); wherein the compounds may be suitable for use for the treatment of bacterial infections. A first embodiment of the invention (Embodiment E1) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined in Formula I in the Summary of the Invention. A second embodiment (Embodiment E2) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is a bond, and all other variables are as defined in Embodiment E1. A third embodiment (Embodiment E3) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is O, and all other variables are as defined in Embodiment E1. A fourth embodiment (Embodiment E4) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is N, and all other variables are as defined in Embodiment E1. A fifth embodiment (Embodiment E5) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is CR1, and R1 is hydrogen, halogen or C1-C3 alkyl optionally substituted with one to three Ra, and all other variables are as defined in Embodiment E1. In a sub-embodiment of Embodiment E5 (Embodiment E5-A), R1 is hydrogen. In another sub-embodiment of Embodiment E5 (Embodiment E5-B), R1 is halogen. In a further sub-embodiment of Embodiment E5 (Embodiment E5-C), R1 is chlorine. In yet another sub-embodiment of Embodiment E5 (Embodiment E5-D), R1 is fluorine. In a further sub-embodiment of Embodiment E5 (Embodiment E5-E), R1 is C1-C3 alkyl optionally substituted with one to three Ra, wherein each occurrence of Ra is independently hydrogen, halogen, C1-C3alkyl, —NRcRd or —ORe. A sixth embodiment (Embodiment E6) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is C1-C3 alkylene optionally substituted with one to three Rb, wherein each occurrence of Rb is independently hydrogen, C1-C8 alkyl, C3-C7 cycloalkyl, —C(O)ORe, —C(O)NRcRd, tetrazolyl, oxadiazolonyl, HetA, AryA, —S(O)mRe, —S(O)mNRcRd, or —P(O)(Re)p, wherein said C1-C8 alkyl and said C3-C7 cycloalkyl are optionally substituted with one to three Ra; and all other variables are as defined in Embodiment E1. In a sub-embodiment of Embodiment E6, Z is C1-C3 alkylene substituted with one occurrence of Rb. In another sub-embodiment of Embodiment E6, Z is C1-C3 alkylene substituted with two occurrences of Rb. In a further sub-embodiment of Embodiment E6, Z is C1-C3 alkylene substituted with three occurrences of Rb. A seventh embodiment (Embodiment E7) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is C1-C3 alkylene substituted with —C(O)ORe; and all other variables are as defined in Embodiment E1. An eighth embodiment (Embodiment E8) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is C1-C3 alkylene substituted with —C(O)OH; and all other variables are as defined in Embodiment E1. A ninth embodiment (Embodiment E9) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is C1-C3 alkylene substituted with tetrazolyl; and all other variables are as defined in Embodiment E1. A tenth embodiment (Embodiment E10) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is C1-C3 alkylene substituted with C1-C8 alkyl, optionally substituted with one to three Ra, and all other variables are as defined in Embodiment E1. An eleventh embodiment (Embodiment E11) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is C1-C3 alkylene substituted with methyl; and all other variables are as defined in Embodiment E1. A twelfth embodiment (Embodiment E12) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is C1-C3 alkylene substituted with methyl and —C(O)OH; and all other variables are as defined in Embodiment E1. A thirteenth embodiment (Embodiment E13) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is —CH(C(O)OH)CH2— and all other variables are as defined in Embodiment E1. A fourteenth embodiment (Embodiment E14) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is C1-C3 alkylene substituted with oxadiazolonyl, and all other variables are as defined in Embodiment E1. A fifteenth embodiment (Embodiment E15) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is a bond, and all other variables are as defined in Embodiment E1. A sixteenth embodiment (Embodiment E16) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is O, and all other variables are as defined in Embodiment E1. A seventeenth embodiment (Embodiment E17) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is NR2, and all other variables are as defined in Embodiment E1. In a sub-embodiment of Embodiment E17, R2 is hydrogen. In another sub-embodiment of Embodiment E17, R2 is C1-C3 alkyl optionally substituted with one to three Ra. In a further sub-embodiment of Embodiment E17, R2 is C(O)Re. In yet another sub-embodiment of Embodiment E17, R2 is —C(O)NRcRd. In still another sub-embodiment of Embodiment E17, R2 is —S(O)mRe. In a further sub-embodiment of Embodiment E17, R2 is —S(O)mNRcRd. An eighteenth embodiment (Embodiment E18) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is S, and all other variables are as defined in Embodiment E1. An nineteenth embodiment (Embodiment E19) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is CH2, and all other variables are as defined in Embodiment E1. A twentieth embodiment (Embodiment E20) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 a 5- to 6-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4, and all other variables are as defined in Embodiment E1. A twenty-first embodiment (Embodiment E21) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is a 5-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4, and all other variables are as defined in Embodiment E1. A twenty-second embodiment (Embodiment E22) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is a 6-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4, and all other variables are as defined in Embodiment E1. In a sub-embodiment of Embodiment E21 or E22, A1 has 1 ring atoms independently selected from N, N as a quaternary salt, O and S. In a further sub-embodiment of Embodiment E21 or E22, A1 has 2 ring atoms independently selected from N, N as a quaternary salt, 0 and S. In another sub-embodiment of Embodiment E21 or E22, A1 has 2 ring atoms independently selected from N, N as a quaternary salt, O and S. In yet another sub-embodiment of Embodiment E21 or E22, A1 has 3 ring atoms independently selected from N, N as a quaternary salt, O and S. A twenty-third embodiment (Embodiment E23) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is an 6-membered monocyclic aromatic ring, optionally substituted with one to four R4, and all other variables are as defined in Embodiment E1. A twenty-fourth embodiment (Embodiment E24) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is an unsubstituted 6-membered monocyclic aromatic ring, and all other variables are as defined in Embodiment E1. A twenty-fifth embodiment (Embodiment E25) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is: and all other variables are as defined in Embodiment E1. A twenty-sixth embodiment (Embodiment E26) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is a bond, and all other variables are as defined in Embodiment E1. A twenty-seventh embodiment (Embodiment E27) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is CH2, and all other variables are as defined in Embodiment E1. A twenty-eighth embodiment (Embodiment E28) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is O, and all other variables are as defined in Embodiment E1. A twenty-ninth embodiment (Embodiment E29) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is S, and all other variables are as defined in Embodiment E1. A thirtieth embodiment (Embodiment E30) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is —(CH2)nNR3—, and all other variables are as defined in Embodiment E1. A thirty-first embodiment (Embodiment E31) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is —NR3(CH2)n—, and all other variables are as defined in Embodiment E1. A thirty-second embodiment (Embodiment E32) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is NH, and all other variables are as defined in Embodiment E1. A thirty-third embodiment (Embodiment E33) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is N(C1-C3 alkyl) optionally substituted with one to three Ra, and all other variables are as defined in Embodiment E1. A thirty-fourth embodiment (Embodiment E34) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is C3-C7 cycloalkyl optionally substituted with one to four R4; and all other variables are as defined in Embodiment E1. A thirty-fifth embodiment (Embodiment E35) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is AryC; and all other variables are as defined in Embodiment E1. A thirty-sixth embodiment (Embodiment E36) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is a 5-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4; and all other variables are as defined in Embodiment E1. A thirty-seventh embodiment (Embodiment E37) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is a 6-membered monocyclic aromatic ring with 0, 1, 2, or 3 ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4, and all other variables are as defined in Embodiment E1. A thirty-eighth embodiment (Embodiment E38) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is HetC; and all other variables are as defined in Embodiment E1. A thirty-ninth embodiment (Embodiment E39) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is a 4- to 7-membered saturated or monounsaturated monocyclic ring with 1 heteroatom ring atom selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4; and all other variables are as defined in Embodiment E1. A fortieth embodiment (Embodiment E40) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is a 4- to 7-membered saturated or monounsaturated monocyclic ring with 2 heteroatom ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4; and all other variables are as defined in Embodiment E1. A forty-first embodiment (Embodiment E41) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is a 4- to 7-membered saturated or monounsaturated monocyclic ring with 3 heteroatom ring atoms independently selected from N, N as a quaternary salt, O and S, optionally substituted with one to four R4; and all other variables are as defined in Embodiment E1. In sub-embodiments of Embodiments E34-E41, A2 is unsubstituted. In other sub-embodiments, A2 is substituted with one R4. In further sub-embodiments A2 is substituted with two R4. In additional sub-embodiments, A2 is substituted with three R4. In still further sub-embodiments, A2 is substituted with four R4. In sub-embodiments of Embodiments E34-E41, A2 is substituted with methyl. In additional sub-embodiments, A2 is substituted with —NH2. In further sub-embodiments, A2 is substituted with ═NH. In other sub-embodiments, A2 is substituted with one to four substitutents selected from: ═NH, —NH2, and —CH3. A forty-second embodiment (Embodiment E42) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: wherein * indicates attachment to Q and ** indicates attachment to M, and all other variables are as defined in Embodiment E1. A forty-third embodiment (Embodiment E43) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A forty-fourth embodiment (Embodiment E44) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A forty-fifth embodiment (Embodiment E45) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A forty-sixth embodiment (Embodiment E46) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A forty-seventh embodiment (Embodiment E47) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A forty-eighth embodiment (Embodiment E48) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A forty-ninth embodiment (Embodiment E49) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A fiftieth embodiment (Embodiment E50) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A fifty-first embodiment (Embodiment E51) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A fifty-second embodiment (Embodiment E52) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A fifty-third embodiment (Embodiment E53) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A fifty-fourth embodiment (Embodiment E54) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A fifty-fifth embodiment (Embodiment E55) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A fifty-sixth embodiment (Embodiment E56) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A fifty-seventh embodiment (Embodiment E57) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A fifty-eighth embodiment (Embodiment E58) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is: and all other variables are as defined in Embodiment E1. A fifty-ninth embodiment (Embodiment E59) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is defined in any of Embodiments E34-E58, M is R5, and all other variables are as defined in Embodiment E1. A sixtieth embodiment (Embodiment E60) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is defined in any of Embodiments E34-E58, M is C2-C10 alkyl optionally substituted with one to four R6, and all other variables are as defined in Embodiment E1. A sixty-first embodiment (Embodiment E61) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is defined in any of Embodiments E34-E58, M is C3-C7 cycloalkyl optionally substituted with one to four R6, and all other variables are as defined in Embodiment E1. A sixty-second embodiment (Embodiment E62) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5, E5-A, E5-B, E5-C, E5-D, or E5-E, Z is defined in any of Embodiments E6-E13, Y is defined in any of Embodiments E15-E19, A1 is defined in any of Embodiments E20-E25, Q is defined in any of Embodiments E26-E33, A2 is defined in any of Embodiments E34-E58, M is HetB, and all other variables are as defined in Embodiment E1. A sixty-third embodiment (Embodiment E63) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein W is defined in Embodiment E2 or E3, X is defined in any of Embodiment E4, E5,
{'application_number': '<application-reference appl-type="utility">\n<document-id>\n<country>US</country>\n<doc-number>15775487</doc-number>\n<date>20161212</date>\n</document-id>\n</application-reference>', 'publication_number': '<publication-reference>\n<document-id>\n<country>US</country>\n<doc-number>20180339983</doc-number>\n<kind>A1</kind>\n<date>20181129</date>\n</document-id>\n</publication-reference>', 'source_file': './application/2018/ipa181129.xml', 'source_data': 'USPTO-Application'}